DFIB Cardiac Science (MM)

Follow-on Purchase Expands Initial 2002 Deployment IRVINE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automatic public-access defibrillators (AEDs) and provider of comprehensive AED/CPR training and AED program management services, announced today that the U.S. Department of Health and Human Services Centers for Disease Control and Prevention (CDC) in Atlanta has purchased more than 150 Powerheart(R) AEDs. Cardiac Science originally won a contract in 2002 to deploy first generation Powerheart AEDs throughout CDC's Atlanta campus. This quarter, the CDC extended its deployment by purchasing additional Powerheart G3 fully- automatic AEDs to expand their availability throughout the CDC's southeastern U.S. locations. "The CDC is the nation's leading federal agency assigned to protect the health of our nation's citizens and we welcome the opportunity to continue to work with the CDC to expand their workplace AED program," said Raymond W. Cohen, Cardiac Science Chairman and CEO. "The CDC order, along with other recently announced U.S. military contracts, is testament to Cardiac Science's ability to compete for, and win contracts based on the merits of our AED technology, customer service and comprehensive program management services. The corporate and government workplace market is the largest segment of the domestic AED market. We will continue to leverage our extensive customer base and relationships in order to capture an increasing share of this large and growing market segment." About the Centers for Disease Control and Prevention The Centers for Disease Control and Prevention, located in Atlanta, is an agency of the U.S. Department of Health and Human Services. The CDC is recognized as the lead federal agency for protecting the health and safety of people -- at home and abroad, providing credible information to enhance health decisions, and promoting health through strong partnerships. CDC serves as the national focus for developing and applying disease prevention and control, environmental health, and health promotion and education activities designed to improve the health of the people of the United States. CDC seeks to accomplish its mission by working with partners throughout the nation and world to monitor health, detect and investigate health problems, conduct research to enhance prevention, develop and advocate sound public health policies, implement prevention strategies, promote healthy behaviors, foster safe and healthful environments, and provide leadership and training. CDC has developed and sustained many vital partnerships with public and private entities that improve service to the American people. The workforce of CDC is comprised of approximately 8,500 people working in 170 disciplines with a public health focus. Although CDC's national headquarters is in Atlanta, more than 2,000 CDC employees work at other locations, including 47 state health departments. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automatic public-access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Cardiac Science has based these forward-looking statements on the current expectations, assumptions, estimates and projections. While Cardiac Science believes the CDC deployment to be a benefit to that organization and will save lives, and that Cardiac Science can capture an increased share of the U.S. workplace AED market segment, these expectations, assumptions, estimates and projections, while reasonable, are forward-looking statements and are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Certain factors, including those discussed in Cardiac Sciences' Annual Report on Form 10-K for the year ended December 31, 2004, under the heading "Risk Factors," may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. Contact: Matt Clawson (Investors) Michael D. Gioffredi Len Hall (Media) Chief Marketing Officer Allen & Caron Inc Cardiac Science, Inc. +1-949-474-4300 (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), , or Len Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright